Pulmonary Arterial Hypertension (PAH) Animal Model Service

Download

A complex and progressive disorder characterized by profound vasoconstriction and pathological remodeling of the pulmonary arterioles, pulmonary arterial hypertension (PAH) drives sustained elevation in pulmonary vascular resistance, ultimately culminating in right ventricular failure and premature mortality.

As a dedicated preclinical research service provider, Protheragen delivers end-to-end, customized PAH animal model development and comprehensive preclinical services, empowering clients to rigorously evaluate novel therapeutics with precision and translational relevance.

Overview of Pulmonary Arterial Hypertension (PAH) Animal Model

Designed to recapitulate the hallmark hemodynamic, histopathological, and molecular features of human PAH, available animal models serve as indispensable tools for elucidating disease pathogenesis and validating therapeutic candidates. Comprising monocrotaline (MCT)-induced, hypoxia-induced, Sugen/hypoxia (SuHx)-induced, and genetic or surgical models, each platform offers distinct mechanistic insights, ranging from endothelial dysfunction and smooth muscle proliferation to in situ thrombosis and perivascular inflammation. Reproducible induction of elevated right ventricular systolic pressure (RVSP), progressive right ventricular hypertrophy (RVH), and occlusive vascular remodeling forms the foundation for reliable efficacy assessments in the preclinical setting.

Applications of Pulmonary Arterial Hypertension (PAH) Animal Model

Facilitating a deeper understanding of disease progression and drug efficacy, these models are utilized across several critical stages of the drug development lifecycle. Their implementation allows for the rigorous assessment of both functional and structural improvements in the pulmonary vasculature and right heart.

Workflow for Pulmonary Arterial Hypertension (PAH) Animal Model Development

• Study Design and Model Selection: Determines the optimal induction method (e.g., monocrotaline or Sugen/hypoxia), species (rat or mouse), strain, sex, and dosing timeline aligned with the therapeutic mechanism of interest.
• Model Induction: Performs standardized model induction followed by baseline hemodynamic, echocardiographic, and body weight assessments to ensure uniform group allocation prior to initiation of therapy.
• Dosing and Experimental Intervention: Administers test articles, positive controls, or vehicle according to a predefined schedule, with flexibility to accommodate various routes (oral, intravenous, subcutaneous, inhalation) and dosing frequencies.
• In-Life Assessments: Conducts serial evaluations, including echocardiography for pulmonary artery acceleration time (PAAT), right ventricular function, and chamber dimensions, alongside body weight monitoring throughout the study duration.
• Terminal Hemodynamic Measurements: Execution of invasive right heart catheterization or P-V loop analysis to capture critical endpoints such as RVSP and cardiac output under anesthesia.
• Necropsy and Tissue Collection: Performs systematic harvest of heart, lungs, and pulmonary arteries with precise separation of right ventricle (RV), left ventricle plus septum (LV+S), and lung lobe processing for downstream histological and molecular analyses.
• Comprehensive Endpoint Analysis: Delivers full datasets encompassing right ventricular hypertrophy (RVH) index, histomorphometric quantification of vascular remodeling (medial wall thickness, occlusive lesion scoring), immunohistochemistry (e.g., α-SMA, Ki67), and biochemical assays as specified per study objectives.

Integrated Preclinical Research Services for PAH

Case Study 01-Monocrotaline (MCT)-induced PAH Model

A single subcutaneous injection of monocrotaline (MCT) was employed to establish a well-characterized rodent model of pulmonary arterial hypertension. Key hemodynamic and structural endpoints were assessed to evaluate model fidelity and therapeutic intervention. The right ventricular hypertrophy index (RVHI), calculated as the ratio of right ventricle weight to left ventricle plus septum weight (RV/(LV+S)), was significantly elevated in MCT-challenged animals, indicating pressure overload-induced remodeling. This increase was markedly attenuated following treatment with the test compound. Similarly, lung wet weight was significantly elevated in MCT-treated rats, reflecting pulmonary edema and inflammatory changes; this increase was reversed in the treatment group.

Echocardiographic assessment provided functional correlation to structural findings. The ratio of pulmonary artery acceleration time to ejection time (PAAT/PET), a well-validated surrogate for pulmonary artery pressure, was significantly reduced in MCT-induced animals, reflecting increased right ventricular afterload. Therapy with the compound restored the PAAT/PET ratio toward control levels, demonstrating functional improvement in pulmonary hemodynamics.

These results demonstrate the utility of the MCT-induced PAH model in capturing both structural remodeling and functional hemodynamic endpoints, thereby enabling a robust evaluation of therapeutic candidates within a well-validated translational framework.

Case Study 02-SU5416/Hypoxia (Su/Hx)-induced PAH Rat Model

Injection of the vascular endothelial growth factor receptor (VEGFR) inhibitor SU5416, combined with sustained exposure to chronic hypoxia followed by return to normoxic conditions, was used to establish the Su/Hx-induced PAH model. Structural and hemodynamic consequences were evaluated across key endpoints. Right ventricular hypertrophy index (RVHI) was significantly elevated in Su/Hx animals, indicative of severe hypertrophic remodeling in response to chronic pressure overload. This pathological increase was substantially attenuated following therapy with the test compound. Lung wet weight, reflecting pulmonary vascular congestion and inflammatory changes, was similarly elevated in vehicle-treated Su/Hx animals and was reduced in the therapy group.

Quantitative morphometric analysis of pulmonary arterioles was performed to assess the extent of vascular remodeling. Su/Hx-induced animals exhibited significant increases across all measured parameters, including media wall thickness (μm), percent media wall thickness (WT%), media wall area (μm²), and percent media wall area (WA%). These structural alterations, characteristic of sustained endothelial injury and smooth muscle proliferation, were markedly diminished in animals receiving the intervention, demonstrating the model’s capacity to detect therapeutic modulation of advanced vascular pathology.

These results underscore the utility of the Su/Hx-induced PAH model in capturing severe vascular remodeling with occlusive and plexiform-like lesions, providing a rigorous platform for evaluating therapeutic candidates in a setting that closely mirrors the pathological complexity of advanced human PAH.

Why Choose Us?

• End-to-End Customization: Full flexibility in study design, from model selection and dosing regimen optimization to customized endpoint selection, ensuring alignment with unique therapeutic mechanisms and regulatory requirements.
• Integrated Translational Platform: A combination of animal model development with in vitro pharmacology, histopathology, and biomarker analysis, accelerating research timelines.
• Rigor and Reproducibility: Strict adherence to standardized operating procedures, data analysis, and robust statistical frameworks to deliver high-quality, reproducible datasets that support informed go/no-go decisions.

Contact Us

Delivering relevant and rigorously characterized PAH animal models tailored to specific therapeutics, the platform provides the precision and scalability for drug development programs. Leveraging deep expertise in pulmonary vascular pathophysiology, integrated preclinical capabilities, and a commitment to scientific excellence, Protheragen serves as a trusted partner in advancing next-generation therapies for pulmonary arterial hypertension. For further details on model capabilities, study design, or to initiate a collaboration, please contact our scientific team.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Rare Disease Diagnostics Development
• Rare Disease Therapeutics Development
• Drug Repurposing Service
• Rare Disease Model Development Services
• Drug Safety Evaluation Services
• Pharmacokinetics Services